Zhuhai Rundu Pharmaceutical

What Zhuhai Rundu Pharmaceutical does

Zhuhai Rundu Pharmaceutical Co., Ltd. (珠海润都制药股份有限公司, SZSE: 002923) is a vertically integrated Chinese pharmaceutical manufacturer founded in 1999 (predecessor entity Mintong Drug Research Institute established 1997) and headquartered in Zhuhai, Guangdong. The company operates across three product layers — pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations — with therapeutic focus on cardiovascular (sartan-class antihypertensives), gastrointestinal (proton pump inhibitors including rabeprazole), anesthesia, anti-infective, and endocrine segments. Its core technology platform centers on enteric-coated and sustained/controlled-release micro-pellet formulation technology and specialized manufacturing for sartan-class and PPI APIs, with the Jingmen subsidiary housing 11 production workshops and a planned 4,000-ton annual capacity for APIs and intermediates.

The company generates revenue through three primary streams: domestic formulation sales via the wholly-owned Mintong Pharmaceutical subsidiary using provincial distribution networks covering hospitals and retail pharmacies; international API and intermediate sales to 200+ customers across 25 countries in North America, Latin America, EU, Russia, Central Asia, Africa, Middle East, South Asia, Southeast Asia, Japan, and Korea; and CMO/CDMO contract manufacturing services. Named strategic enterprise customers include Sanofi, Sandoz, Hengrui Medicine, and Yangtze River Pharma. Regulatory certifications include US FDA (on-site inspection passed July 2025), EU EDQM CEP, WHO PQ, ANVISA, Japan PMDA, and Korea MFDS, providing the regulatory moat that enables global market access. R&D is conducted via a Wuhan-based research institute subsidiary, a US R&D center, and a New Zealand formulation partner, supported by a 200+ person R&D team with 30+ PhDs and a National Post-Doctoral Research Workstation.

The company has 1,600-2,000 full-time employees, holds 232 patents (104 invention patents), and has received 4 national key new product certifications. In April 2026, it received NMPA approval for Denopreg Hydrochloride Injection, a Class 1 innovative drug and world's first approved beta-receptor agonist for nuclear medicine myocardial perfusion imaging cardiac stress testing. Financial data shows a multi-year contraction pattern with revenue declining from approximately $1,372M in 2022 to $1,176M in 2025, gross profit falling from $771M to $454M, and net income turning negative at -$63M in 2025, reflecting margin pressure likely tied to China's National Centralized Drug Procurement program and generic pricing competition. The company is publicly listed on the Shenzhen Stock Exchange with no parent company and standard public governance structure.

Name

Zhuhai Rundu Pharmaceutical

Legal name

珠海润都制药股份有限公司

Website

https://rdpharma.cn

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zhuhai Rundu Pharmaceutical is a vertically integrated Chinese generic pharmaceutical manufacturer producing intermediates, APIs, and finished formulations across cardiovascular, gastrointestinal, anesthesia, and anti-infective therapeutic areas, serving global B2B customers including Sanofi and Sandoz with FDA/EDQM-certified manufacturing.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Cardiovascular formulations
• Contract manufacturing services

Headquarters

HQ city

Zhuhai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Formulation Product Sales (Domestic): Domestic sales of finished dosage forms through subsidiary Mintong Pharma covering cardiovascular, gastrointestinal, endocrine and other therapeutic areas via hospital and retail pharmacy channels
2. API and Intermediate Export: International and domestic sales of active pharmaceutical ingredients and pharmaceutical intermediates, including sartan drugs and other APIs to global pharmaceutical customers
3. CMO/CDMO Contract Manufacturing: Custom manufacturing organization services for APIs and finished dosage forms including registered starting materials, GMP intermediates, commercial scale APIs, and oral solids with modified release technology

Go-to-market motion4 records

Distribution channels4 records

Marketing channels3 records

Core offering

Zhuhai Rundu Pharmaceutical is a vertically integrated pharmaceutical manufacturer producing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), specialized enteric-coated and sustained-release pellets, and finished dosage forms (tablets, capsules, injections) across cardiovascular, gastrointestinal, anesthesia, anti-infective, and endocrine therapeutic areas. The company also provides CMO/CDMO contract manufacturing services for APIs and oral solid dosage forms with modified release technology to global pharmaceutical customers.

Product overview

Zhuhai Rundu Pharmaceutical (润都股份, stock code 002923) operates as a vertically integrated pharmaceutical manufacturer with three main product lines: chemical pharmaceutical preparations (制剂), active pharmaceutical ingredients (原料药/APIs), and pharmaceutical intermediates (中间体). The company also produces specialized enteric-coated and sustained-release pellets as intermediate products. Core therapeutic areas include cardiovascular (沙坦类降压药, 氨氯地平), gastrointestinal (拉唑类PPI, 伊托必利), anti-infective (阿奇霉素, 伏立康唑), pain relief/NSAIDs (布洛芬, 双氯芬酸钠), anesthesia (左布比卡因, 利多卡因), and endocrine (二甲双胍). The company holds leading positions in sartan and lansoprazole API manufacturing globally. Key finished formulations include branded products like 雷贝拉唑钠肠溶胶囊 (雨田青), while 1类创新药盐酸去甲乌药碱注射液 represents the world's first approved β-receptor agonist for cardiac stress testing. The company operates through subsidiaries: Mintong Pharmaceutical for domestic formulation marketing, Wuhan Research Institute for R&D, and Jingmen facility for large-scale API manufacturing. International operations serve pharmaceutical giants including Sanofi and Sandoz.

Differentiator

Problem solved

Functional benefit

Brands

• 民彤医药 (Mintong Pharmaceutical): Wholly-owned subsidiary focusing on domestic formulation sales and brand services
• 健康伊家 (Health Yijia)

Products and services

• Rabeprazole Sodium Enteric Capsules (雷贝拉唑钠肠溶胶囊) - Yutianqing (雨田青) Enteric-coated capsule formulation for the treatment of acid-related gastrointestinal disorders, providing protection against gastric acid degradation; flagship branded product Yutianqing recognized in 2024 China Pharmaceutical Brand List.
• Valsartan Tablets (缬沙坦片) Cardiovascular medication for the treatment of hypertension and heart failure; angiotensin receptor blocker finished dosage form.
• Isosorbide Mononitrate Tablets / Sustained Release Capsules (单硝酸异山梨酯片/缓释胶囊) Anti-anginal medication for the prevention and treatment of angina pectoris associated with coronary heart disease.
• Olmesartan Medoxomil and Amlodipine Besylate Tablets (奥美沙坦酯氨氯地平片) Combination cardiovascular medication for hypertension combining an angiotensin receptor blocker with a calcium channel blocker for dual-action blood pressure control.
• Valsartan and Amlodipine Tablets (缬沙坦氨氯地平片) Combination antihypertensive medication providing dual action angiotensin receptor blocker plus calcium channel blocker for blood pressure control.
• Irbesartan Tablets / Capsules (厄贝沙坦片/胶囊) Angiotensin receptor blocker finished dosage form for the treatment of hypertension and renal protection in type 2 diabetes.
• Levobupivacaine Hydrochloride Injection (盐酸左布比卡因注射液) Long-acting local anesthetic for surgical anesthesia and postoperative pain management.
• Ibuprofen Sustained-release Capsules (布洛芬缓释胶囊) NSAID with sustained-release formulation for extended pain relief and anti-inflammatory action.
• Diclofenac Sodium Sustained Release Capsules (双氯芬酸钠缓释胶囊) NSAID with sustained-release formulation for management of pain and inflammation in osteoarthritis and rheumatoid arthritis.
• Omeprazole Enteric Capsules (奥美拉唑肠溶胶囊) Proton pump inhibitor for treating acid-related conditions including GERD, peptic ulcers, and H. pylori infection.
• Itopride Hydrochloride Capsules / Tablets (盐酸伊托必利胶囊/片) Prokinetic agent for the treatment of functional gastrointestinal disorders including dyspepsia.
• Azithromycin Enteric-coated Capsules (阿奇霉素肠溶胶囊) Macrolide antibiotic for treating respiratory infections, skin infections, and other bacterial diseases.
• Metformin Hydrochloride Enteric Capsules (盐酸二甲双胍肠溶胶囊) First-line antidiabetic medication for type 2 diabetes management with enteric coating for improved tolerability.
• Voriconazole for Oral Suspension (伏立康唑干混悬剂) Antifungal medication for treating serious invasive fungal infections.
• Denopreg Hydrochloride Injection (盐酸去甲乌药碱注射液) - Class 1 Innovative Drug World's first approved β-receptor agonist nuclear medicine myocardial perfusion imaging cardiac stress test drug; China's first Class 1 innovative drug from the company.
• Valsartan API (原料药 - 缬沙坦) Angiotensin receptor blocker API with FDA DMF #32328 and CEP certification for antihypertensive applications.
• Irbesartan API (原料药 - 厄贝沙坦) Angiotensin receptor blocker API with FDA DMF #32803 for cardiovascular applications.
• Candesartan Cilexetil API (原料药 - 坎地沙坦酯) Angiotensin receptor blocker API with FDA DMF #37468 for hypertension treatment.
• Olmesartan Medoxomil API (原料药 - 奥美沙坦酯) Angiotensin receptor blocker API with FDA DMF #34941 for cardiovascular applications.
• Telmisartan API (原料药 - 替米沙坦) Angiotensin receptor blocker API for hypertension and cardiovascular protection.
• Sacubitril/Valsartan API (原料药 - 沙库巴曲缬沙坦钠) Combination API for heart failure treatment with FDA DMF #35868.
• Rabeprazole Sodium API (原料药 - 雷贝拉唑钠) Proton pump inhibitor API for treating acid-related gastrointestinal disorders.
• Lansoprazole API (原料药 - 兰索拉唑) Proton pump inhibitor API for peptic ulcer and GERD treatment.
• Mesalazine API (原料药 - 美沙拉嗪) Anti-inflammatory API for inflammatory bowel disease treatment.
• Amlodipine Besylate API (原料药 - 苯磺酸氨氯地平) Calcium channel blocker API for hypertension and angina treatment.
• Sartan-class Pharmaceutical Intermediates (沙坦类中间体) Key intermediates for sartan class antihypertensive drug synthesis including valsartan, irbesartan, candesartan, olmesartan, losartan, and telmisartan.
• Sacubitril Series Intermediates (沙库巴曲系列中间体) Intermediates for sacubitril API production used in heart failure medications.
• Quinolone / Florfenicol Intermediates (喹诺酮类/氟苯尼考类中间体) Intermediates for quinolone antibiotics and florfenicol production.
• Rabeprazole Sodium Enteric-coated Pellets (雷贝拉唑钠肠溶微丸) Enteric-coated pellets at 5.3% specification for antiulcerative applications; pellet intermediate product.
• Omeprazole Enteric-coated Pellets (奥美拉唑肠溶微丸) Enteric-coated pellets at 8.5% specification for acid suppression.
• Lansoprazole Enteric-coated Pellets (兰索拉唑肠溶微丸) Enteric-coated pellets at 9.0% specification for antiulcerative applications.
• Ibuprofen Sustained Release Pellets (布洛芬缓释微丸) Sustained-release pellets at 72% specification for anti-inflammatory applications.
• Isosorbide Mononitrate Sustained Release Pellets (单硝酸异山梨酯缓释微丸) Sustained-release pellets at 30% specification for anti-anginal applications.
• CMO / CDMO Contract Manufacturing Services Custom manufacturing organization services for APIs and finished dosage forms including registered starting materials, GMP intermediates, commercial scale APIs, and oral solids with modified release technology.
• Health Yijia (健康伊家) Chronic Disease Management Platform Non-profit chronic disease health management sub-brand with over 100,000 members supporting chronic disease patient education and management.

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and important.

• Sanofi (赛诺菲)coreStrategic or Co-development PartnerStrategic partnership for pharmaceutical products, leveraging Rundu's API manufacturing capabilities and global regulatory certifications
• Sandoz (山德士)coreStrategic or Co-development PartnerStrategic partnership with Novartis subsidiary Sandoz for generic pharmaceutical products, providing high-quality APIs for global markets
• Hengrui Medicine (恒瑞)coreStrategic or Co-development PartnerStrategic partnership with leading Chinese pharmaceutical company Hengrui Medicine for domestic market collaboration
• Yangtze River (正大天晴)coreStrategic or Co-development PartnerStrategic partnership with major Chinese pharmaceutical company for product supply and market cooperation
• NovartiscoreStrategic or Co-development PartnerStrategic partnership for pharmaceutical products leveraging Rundu's quality APIs and regulatory certifications
• Five Leading Domestic UniversitiesimportantStrategic or Co-development PartnerIndustry-university-research cooperation with five leading domestic pharmaceutical universities for joint research and talent development
• International Research InstitutionsimportantStrategic or Co-development PartnerCollaborative R&D partnerships with international top research institutions for advanced formulation technology development
• US R&D CenterimportantTechnology or IntegrationR&D center in the United States engaged in developing cutting-edge technology, high-end generic and new medicines

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Livzon Pharmaceutical Group: Diversified Chinese pharma with strong GI franchise (including PPIs like rabeprazole/omeprazole) and API manufacturing capabilities. Comparable for PPI therapeutic focus and integrated manufacturing model.
• Yangtze River Pharmaceutical (Chia Tai Tianqing): One of China's largest privately-held pharmaceutical groups with significant cardiovascular and PPI franchises. Comparable as a broad incumbent across Rundu's core therapeutic categories, with similar generic-and-API business mix.
• CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharmaceutical group with extensive API and formulation operations across cardiovascular and other therapeutic areas. Comparable as a broad incumbent with overlapping product categories and international footprint.
• Hengrui Medicine: China's largest innovative pharmaceutical company, and a named strategic partner of Rundu. Comparable as a broad incumbent in Chinese pharmaceuticals with overlapping cardiovascular and GI portfolios, but at materially larger scale and innovation orientation.
• Yiling Pharmaceutical: Chinese pharmaceutical manufacturer with cardiovascular and generic drug focus. Comparable for cardiovascular therapeutic area overlap and Chinese generic pharma positioning, though with greater emphasis on TCM-adjacent products.

Direct peers

• Salubris Pharmaceuticals: Chinese pharmaceutical company with cardiovascular API focus (including sartans) and growing formulation business. Closely comparable for cardiovascular therapeutic focus and API-to-formulation vertical integration.
• Zhejiang Huahai Pharmaceutical: One of China's largest API manufacturers with a strong cardiovascular (sartan) franchise and extensive FDA/EDQM certifications. Directly comparable to Rundu in product mix (sartan APIs + formulations), regulatory posture, and export-oriented business model.
• Apeloa Pharmaceutical: Chinese vertically integrated API and formulation manufacturer with significant cardiovascular and anti-infective API production. Directly comparable for its intermediate-to-formulation chain and global API export orientation.
• Crystal Pharmaceutical (Suzhou): Specialty Chinese API manufacturer with strong cardiovascular and CNS API capabilities plus international regulatory certifications. Comparable as a smaller-scale, export-oriented Chinese API specialist competing in similar regulated markets.

Emerging players

• Asymchem Laboratories: Leading Chinese CDMO with strong small-molecule API and intermediate manufacturing capabilities and global regulatory certifications. Comparable for CMO/CDMO business model and international API export orientation, though more CDMO-weighted vs. Rundu's brand-generic focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zhuhai-rundu-pharmaceutical-co.-ltd.

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhuhai Rundu Pharmaceutical